U.S. markets open in 7 hours 1 minute
  • S&P Futures

    4,117.75
    -6.75 (-0.16%)
     
  • Dow Futures

    32,708.00
    -29.00 (-0.09%)
     
  • Nasdaq Futures

    12,990.25
    -41.25 (-0.32%)
     
  • Russell 2000 Futures

    1,910.20
    -4.40 (-0.23%)
     
  • Crude Oil

    89.62
    -0.88 (-0.97%)
     
  • Gold

    1,804.10
    -8.20 (-0.45%)
     
  • Silver

    20.35
    -0.13 (-0.64%)
     
  • EUR/USD

    1.0211
    -0.0006 (-0.06%)
     
  • 10-Yr Bond

    2.7970
    0.0000 (0.00%)
     
  • Vix

    21.77
    +0.48 (+2.25%)
     
  • GBP/USD

    1.2071
    -0.0005 (-0.04%)
     
  • USD/JPY

    135.0800
    -0.0360 (-0.03%)
     
  • BTC-USD

    22,890.60
    -896.26 (-3.77%)
     
  • CMC Crypto 200

    531.26
    -26.09 (-4.68%)
     
  • FTSE 100

    7,488.15
    +5.78 (+0.08%)
     
  • Nikkei 225

    27,819.33
    -180.63 (-0.65%)
     

Is There Now An Opportunity In Tabula Rasa HealthCare, Inc. (NASDAQ:TRHC)?

  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

While Tabula Rasa HealthCare, Inc. (NASDAQ:TRHC) might not be the most widely known stock at the moment, it led the NASDAQGM gainers with a relatively large price hike in the past couple of weeks. With many analysts covering the stock, we may expect any price-sensitive announcements have already been factored into the stock’s share price. However, could the stock still be trading at a relatively cheap price? Today I will analyse the most recent data on Tabula Rasa HealthCare’s outlook and valuation to see if the opportunity still exists.

Check out our latest analysis for Tabula Rasa HealthCare

Is Tabula Rasa HealthCare still cheap?

Great news for investors – Tabula Rasa HealthCare is still trading at a fairly cheap price. My valuation model shows that the intrinsic value for the stock is $89.32, but it is currently trading at US$59.35 on the share market, meaning that there is still an opportunity to buy now. What’s more interesting is that, Tabula Rasa HealthCare’s share price is quite volatile, which gives us more chances to buy since the share price could sink lower (or rise higher) in the future. This is based on its high beta, which is a good indicator for how much the stock moves relative to the rest of the market.

Can we expect growth from Tabula Rasa HealthCare?

earnings-and-revenue-growth
earnings-and-revenue-growth

Investors looking for growth in their portfolio may want to consider the prospects of a company before buying its shares. Although value investors would argue that it’s the intrinsic value relative to the price that matter the most, a more compelling investment thesis would be high growth potential at a cheap price. Tabula Rasa HealthCare's earnings over the next few years are expected to increase by 23%, indicating a highly optimistic future ahead. This should lead to more robust cash flows, feeding into a higher share value.

What this means for you:

Are you a shareholder? Since TRHC is currently undervalued, it may be a great time to increase your holdings in the stock. With an optimistic outlook on the horizon, it seems like this growth has not yet been fully factored into the share price. However, there are also other factors such as financial health to consider, which could explain the current undervaluation.

Are you a potential investor? If you’ve been keeping an eye on TRHC for a while, now might be the time to enter the stock. Its buoyant future outlook isn’t fully reflected in the current share price yet, which means it’s not too late to buy TRHC. But before you make any investment decisions, consider other factors such as the track record of its management team, in order to make a well-informed investment decision.

In light of this, if you'd like to do more analysis on the company, it's vital to be informed of the risks involved. Case in point: We've spotted 4 warning signs for Tabula Rasa HealthCare you should be aware of.

If you are no longer interested in Tabula Rasa HealthCare, you can use our free platform to see our list of over 50 other stocks with a high growth potential.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.